摘要:
A butenoic acid compound is defined by the following formula: in which Z is O,S, vinylene or azomethyne, A is an alkylene and J is phenyl or etc. It is useful to treat the heart disease.
摘要:
A butenoic acid compound is defined by the following formula: in which Z is O,S, vinylene or azomethyne, A is an alkylene and J is phenyl or etc. It is useful to treat the heart disease.
摘要:
The invention provides novel compounds of the formu- ' la:
wherein each of R 1 , R 2 and R 3 , which can be the same or different, is hydrogen, chloro, bromo, fluoro, methyl, ethyl, methoxy, amino, hydroxy or nitro; R 4 and R 5 , which can be the same or different, are hydrogen, an alkyl radical of 1 to 7 carbon atoms, hydroxymethyl or R 6 is hydrogen, an alkyl radical of 1 to 7 carbon atoms or R 7 and R 8 are hydrogen, chloro or methyl; X is-CH=CH- or CHR 9 ; Rg is hydrogen or hydroxy; n is 0-7 and m is 0-6; and their non-toxic pharmaceutically acceptable acid addition salts and mixtures thereof. Processes for the preparation of these compounds are described, as are novel pharmaceutical compositions comprising at least one of the compounds and their salts. The compounds and their non-toxic salts exhibit valuable pharmacological activity and are useful in the treatment of mammals, especially as antihypertensives and also as antithrombotic and antimycotic agents.
摘要翻译:本发明提供新的下式化合物:其中R 1,R 2和R 3各自可以相同或不同,是氢,氯,溴,氟,甲基,乙基,甲氧基,氨基,羟基或硝基; R 4和R 5可以相同或不同,为氢,1至7个碳原子的烷基,羟甲基或CHEM R 6为氢,1至7个碳原子的烷基或 R 7和R 8 是氢,氯或甲基; X是-CH = CH-或CHR 9; R9是氢或羟基; n为0-7,m为0-6; 及其无毒的药学上可接受的酸加成盐及其混合物。 描述了制备这些化合物的方法,以及包含至少一种化合物及其盐的新型药物组合物。 化合物及其无毒盐显示出有价值的药理活性,并且可用于哺乳动物的治疗,特别是作为抗高血压药物以及抗血栓形成和抗真菌剂。
摘要:
This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula:
wherein: A is an aryl group; Q 1 is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: -NR 1 (=O)- and -C(=O)NR 1 -; R 1 is an amido substituent; and, Q 2 is an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, and ethers thereof, for use in the treatment of a fibroproliferative disorder; liver fibrosis; smooth muscle proliferative disorder; atherosclerosis; restenosis; a neurodegenative disease; Alzheimer's; Parkinson's; Huntington's chorea; amyotropic lateral sclerosis; spino-cerebellar degeneration; an inflammatory disease; osteoarthritis; rheumatoid arthritis; a diseases involving angiogenesis; diabetic retinopathy; a haematopoietic disorder; anaemia; sickle cell anaemia; thalassaeimia; a fungal infection; a parasitic infection; trypanosomiasis; helminthiasis; a protozoal infection; a bacterial infection; a viral infection; a condition treatable by immune modulation; multiple sclerosis; autoimmune diabetes; lupus; atopic dermatitis; an allergy; asthma; allergic rhinitis; or inflammatory bowel disease.
摘要:
This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: wherein: A is an aryl group; Q is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: -NR C(=O)- and -C(=O)NR -; R is an amido substituent; and, Q is an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof, for use in the treatment of parasitic infections, such as malaria.
摘要:
This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: wherein: A is an aryl group; Q is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: -NR C(=O)- and -C(=O)NR -; R is an amido substituent; and, Q is an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof, for use in the treatment of parasitic infections, such as malaria.
摘要:
An imidazoline derivative represented by general formula (1), wherein R1 represents a water- or fat-soluble substituent, in particular, carboxyl or carbomethoxy, or a pharmaceutically acceptable salt group thereof. A process for producing the same. A blood pressure retentive containing as the active ingredient the above imidazoline derivative or another imidazoline derivative wherein R1 in formula (1) represents hydrogen. The above imidazoline derivative is a novel substance, and both this compound and the imidazoline derivative wherein R1 represents hydrogen are useful as the blood pressure retentive for treating hypotensive shock by removing excessive NO which is the substantial ingredient of a vascular smooth muscle relaxant (EDRF).
摘要:
Gegenstand der Anmeldung sind neue N-Hydroxyalkylimidazolinderivate der Formel
worin bedeuten:
R 1 , R 2 = H und/oder unverzweigter C 1 -C 20 -Alkylrest, wobei die Summe der C-Atome in R 1 und R 2 8- 20 ist. R 3 = H oder ein C 1 -C 23 -Alkylrest oder ein Phenylrest oder ein Rest R 5 -A, wobei R 5 ein um die Carboxylgruppen verminderter Rest einer aliphatischen oder aromatischen C 3 -C, 2 -Dicarbonsäure, A ein um R 3 verminderter Hydroxyalkylimidazolinrest ist, R 4 = C 1 -C 20 - Alkyl oder Benryl oder Propylsulfonat, X (-) = beliebiges Anion einer organischen oder anorganischen Säure, insbesondere Ch (-) , X (-) entfällt, wenn R 4 = Propylsulfonat. Weitere Gegenstände der Anmeldung sind die Herstellung der neuen Produkte durch Umsetzung entsprechender N-Hydroxyalkylethylendiamine mit einer Mono-oder Dicarbonsäure bei 120 - 150°C unter Abdestillieren des Reaktionswassers und gegebenenfalls weiterer Umsetzung mit einem Quatenierungsmittel, sowie deren Verwendung als Korrosionsschutzmittel, mikrobizide Mittel, Körper- und Haarwaschmittel oder als Textilavivage- und Textilweichmachungsmittel.